ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma"

Thrombosis Research

Volumn 132, Issue 1, 2013, Pages 56-62

  Sakata, Chinatsu ^a   Kawasaki, Tomihisa ^a   Kato, Yasuko ^a   Abe, Masaki ^a   Suzuki, Ken Ichi ^a   Ohmiya, Makoto ^a   Funatsu, Toshiyuki ^a   Morita, Yoshiaki ^a   Okada, Masamichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Aspirin; Cyclooxygenase; Platelet; Prostaglandin I 2; Thrombosis; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ASP 6537; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; PROSTACYCLIN; PROSTANOID; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; AORTA; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; GUINEA PIG; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STOMACH MUCOSA; STOMACH ULCER; THROMBOCYTE; THROMBOCYTE RICH PLASMA; ULCEROGENESIS;

AA; ACS; ACUTE CORONARY SYNDROME; ARACHIDONIC ACID; ASPIRIN; COX; CYCLOOXYGENASE; DIMETHYLSULFOXIDE; DMSO; GASTROINTESTINAL; GI; MC; MED; METHYLCELLULOSE; MI; MINIMUM EFFECTIVE DOSE; MYOCARDIAL INFARCTION; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; PGI(2); PLATELET; PLATELET-RICH PLASMA; PROSTAGLANDIN I(2); PRP; THROMBOSIS; THROMBOXANE A(2); TIME TO OCCLUSION; TTO; TXA(2);

ANIMALS; ASPIRIN; CAROTID ARTERY THROMBOSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; EPOPROSTENOL; FIBRINOLYTIC AGENTS; GUINEA PIGS; HUMANS; MALE; PROSTAGLANDINS; RATS; STOMACH; TRIAZOLES; ULCER;

EID: 84881316372     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.03.005     Document Type: Article

References (40)

1. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 10 2000 1206 1218 (Pubitemid 30146625)
2. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 22 2005 2373 2383 (Pubitemid 41713749)
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 7329 2002 71 86
4. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, and B. Tournier Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 25 Dec 20 2001 1809 1817
5. J.M. Gaziano, and C.M. Gibson Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection Am J Cardiol 97 9A May 8 2006 23 29
6. W. Tomisato, S. Tsutsumi, T. Hoshino, H.J. Hwang, M. Mio, and T. Tsuchiya Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions Biochem Pharmacol 67 3 2004 575 585 (Pubitemid 38232897)
7. L.A. Garcia Rodriguez, and S. Hernandez-Diaz Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs Am J Epidemiol 159 1 2004 23 31 (Pubitemid 38049418)
8. G.E. Caughey, L.G. Cleland, P.S. Penglis, J.R. Gamble, and M.J. James Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2 J Immunol 167 5 2001 2831 2838 (Pubitemid 32768916)
9. J.R. Vane Biomedicine. Back to an aspirin a day? Science 296 5567 2002 474 475
10. Y. Yu, E. Ricciotti, T. Grosser, and G.A. Fitzgerald The translational therapeutics of prostaglandin inhibition in atherothrombosis J Thromb Haemost 7 Suppl. 1 2009 222 226
11. S. Moncada, R. Gryglewski, S. Bunting, and J.R. Vane An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature 263 5579 Oct 21 1976 663 665
12. P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe, and M. Egger Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 9450 Dec 4-10 2004 2021 2029
13. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 11 2005 1092 1102 (Pubitemid 40365350)
14. J.A. Baron, R.S. Sandler, R.S. Bresalier, A. Lanas, D.G. Morton, and R. Riddell Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial Lancet 372 9651 2008 1756 1764
15. J.L. Gordon, and J.D. Pearson Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells Br J Pharmacol 64 4 Dec 1978 481 483 (Pubitemid 9098880)
16. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 22 Dec 1 2005 2373 2383 (Pubitemid 41713749)
17. A.T. Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 7329 Jan 12 2002 71 86
18. S. Kargman, S. Charleson, M. Cartwright, J. Frank, D. Riendeau, and J. Mancini Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Gastroenterology 111 2 1996 445 454 (Pubitemid 26256734)
19. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120 (Pubitemid 28231490)
20. H. Kakuta, X. Zheng, H. Oda, S. Harada, Y. Sugimoto, and K. Sasaki Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor J Med Chem 51 8 2008 2400 2411 (Pubitemid 351628501)
21. A. Tanaka, H. Araki, S. Hase, Y. Komoike, and K. Takeuchi Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury Aliment Pharmacol Ther 16 Suppl. 2 2002 90 101 (Pubitemid 41771467)
22. J.L. Wallace Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs) Am J Med 107 6A 1999 11S 16S [discussion 6S-7S]
23. J. Imanishi, Y. Morita, E. Yoshimi, K. Kuroda, T. Masunaga, and K. Yamagami Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor Biochem Pharmacol 82 7 2011 746 754
24. J.C. Yao, W.G. Duan, Y. Yun, Q. Liu de, M. Yan, and Z.Z. Jiang Screening method for nonsteroidal antiinflammatory drugs based on the cyclooxygenase 2 pathway activated by serum-free stimulation in A549 cells Yakugaku Zasshi 127 3 Mar 2007 527 532 (Pubitemid 46354418)
25. A. Riutta, E. Nurmi, C. Weber, G. Hansson, H. Vapaatalo, and I. Mucha Selective solid-phase extraction of urinary 2,3-dinor-6-ketoprostaglandin F1 alpha for determination with radioimmunoassay Anal Biochem 220 2 Aug 1 1994 351 359
26. J.L. Johnson, J. Wimsatt, S.D. Buckel, R.D. Dyer, and K.R. Maddipati Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons Arch Biochem Biophys 324 1 1995 26 34
27. C.J. Smith, Y. Zhang, C.M. Koboldt, J. Muhammad, B.S. Zweifel, and A. Shaffer Pharmacological analysis of cyclooxygenase-1 in inflammation Proc Natl Acad Sci U S A 95 22 1998 13313 13318 (Pubitemid 28509568)
28. T. Ochi, Y. Motoyama, and T. Goto The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models Eur J Pharmacol 391 1-2 2000 49 54 (Pubitemid 30138079)
29. Y. Cheng, M. Wang, Y. Yu, J. Lawson, C.D. Funk, and G.A. Fitzgerald Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function J Clin Invest 116 5 2006 1391 1399
30. F. Catella-Lawson, B. McAdam, B.W. Morrison, S. Kapoor, D. Kujubu, and L. Antes Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 2 1999 735 741 (Pubitemid 29191226)
31. C. Bolego, C. Buccellati, A. Prada, R.M. Gaion, G. Folco, and A. Sala Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone FASEB J 23 2 2009 605 612
32. R.L. Matz, M.A. de Sotomayor, C. Schott, J.C. Stoclet, and R. Andriantsitohaina Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids Br J Pharmacol 131 2 2000 303 311
33. M. Feletou, Y. Huang, and P.M. Vanhoutte Vasoconstrictor prostanoids Pflugers Arch 459 6 2010 941 950
34. E. Vericel, M. Croset, P. Sedivy, P. Courpron, M. Dechavanne, and M. Lagarde Platelets and aging. I-Aggregation, arachidonate metabolism and antioxidant status Thromb Res 49 3 1988 331 342
35. C. Heymes, A. Habib, D. Yang, E. Mathieu, F. Marotte, and J. Samuel Cyclo-oxygenase-1 and - 2 contribution to endothelial dysfunction in ageing Br J Pharmacol 131 4 2000 804 810
36. C.H. Ruan, S.P. So, and K.H. Ruan Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease Life Sci 88 1-2 2011 24 30
37. T. Kawasaki, K. Sato, Y. Sakai, F. Hirayama, H. Koshio, and Y. Taniuchi Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis Thromb Haemost 79 2 1998 410 416 (Pubitemid 28065894)
38. S.A. Mousa, R. Kapil, and D.X. Mu Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459 Arterioscler Thromb Vasc Biol 19 10 1999 2535 2541 (Pubitemid 29477856)
39. J. Lorrain, I. Lechaire, C. Gauffeny, R. Masson, N. Roome, and J.P. Herault Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel J Pharmacol Exp Ther 309 1 2004 235 240 (Pubitemid 38393135)
40. P.C. Wong, E.J. Crain, C.A. Watson, J. Hua, W.A. Schumacher, and R. Rehfuss Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability Thromb Haemost 101 1 2009 108 115